Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE)
Authors:
- Véronique Avettand-FenoelVAVéronique Avettand-Fenoel
- on behalf of the members of the ETOILE studyOSon behalf of the members of the ETOILE study
Open Access
- 28 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 65 (10) , 2212-2214
Abstract
To describe HIV-1 DNA levels from baseline (W0) to week 52 (W52) among patients receiving either interleukin-2 (IL-2) + optimized background therapy (OBT) or OBT as salvage treatment. This was evaluated in a substudy of the ETOILE Agence Nationale de Recherches sur le SIDA et les hépatites virales (ANRS) 123 trial (patients with CD4 ≤ 200/mm3, HIV RNA > 4 log10 copies/mL and a genotypic score showing two or fewer active drugs). OBT included enfuvirtide whenever possible. HIV DNA was quantified with the ANRS assay. Blood samples were available for 21 patients in the IL-2 + OBT arm and 23 in the OBT alone arm at baseline, and for 10 and 17 patients, respectively, at W52. Median baseline CD4 count was 47 cells/mm3 and 68 cells/mm3, respectively; median HIV RNA was 5.1 and 4.9 log10 copies/mL. Baseline median HIV DNA load was 3.44 log10 copies/106 peripheral blood mononuclear cells (PBMCs) (interquartile range 3.31–4.08) and 3.51 (3.18–3.82) log10 copies/106 PBMCs, respectively. At W52, it was 3.18 log10 copies/106 PBMCs (2.75–3.52) and 3.48 log10 copies/106 PBMCs (3.10–3.67), respectively. Cells were available at both W0 and W52 for 7 patients in the IL-2 + OBT arm and 14 in the OBT arm. Change in HIV DNA load was not associated with IL-2 use, but decreased among the seven patients receiving enfuvirtide (−0.22 log10 copies/mL) as compared with the other 14 patients (+0.20 log10; P = 0.046). A steeper decrease in HIV DNA was observed among patients who had a larger increase in CD4 count (Pearson coefficient ρ = 0.659, P = 0.001). Adjusted for enfuvirtide use, there was a trend for an association between upper baseline HIV DNA level and a less frequent CD4 gain ≥50 cells/mm3 at W52 (odds ratio = 0.17, P = 0.075). HIV DNA levels were high in patients with advanced therapeutic failure. A larger viral reservoir may be associated with lower gains in CD4 count among patients receiving OBT. HIV DNA level could be a useful tool for the case management of patients in the late stages of disease.Keywords
This publication has 9 references indexed in Scilit:
- Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patientsAIDS, 2009
- LTR real‐time PCR for HIV‐1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)Journal of Medical Virology, 2008
- HIV-DNA in rectal cells is well correlated with HIV-DNA in blood in different groups of patients, including long-term non-progressorsAIDS, 2008
- CD4 Cell Count and HIV DNA Level Are Independent Predictors of Disease Progression after Primary HIV Type 1 Infection in Untreated PatientsClinical Infectious Diseases, 2006
- Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapyAIDS, 2004
- Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five YearsJournal of Virology, 2003
- Increase of HIV-1 Pro-Viral Dna per Million Peripheral Blood Mononuclear Cells in Patients with Advanced HIV Disease (Cd43 ) Receiving Interleukin 2 Combined with Haart Versus Haart Alone (Anrs-082 Trial)Antiviral Therapy, 2003
- Quantitation of Human Immunodeficiency Virus Type 1 DNA Forms with the Second Template Switch in Peripheral Blood Cells Predicts Disease Progression Independently of Plasma RNA LoadJournal of Virology, 2002
- Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapyAIDS, 2001